Intensive Care Medicine

, Volume 32, Issue 3, pp 371–379 | Cite as

Melatonin: possible implications for the postoperative and critically ill patient

Review

Abstract

There is increasing interest in the hormone melatonin in postoperative and critically ill patients. The roles of melatonin in the regulation of the sleep-wake cycle, resetting of circadian rhythm disturbances and its extensive antioxidant activity have potential applications in these patient groups. The interaction between melatonin and the stresses of surgery and critical illness are explored in the context of circadian rhythms, sleep disorders and delirium. The antioxidant activity is discussed in terms of the reduction of ischaemic reperfusion injury, prevention of multi-organ failure and treatment of sepsis. Unfortunately, there is currently insufficient evidence that exogenous melatonin is effective in preventing or treating postoperative delirium. Similarly, in the critically ill patient, sleep disorders are associated with disrupted melatonin circadian secretion, but there is a paucity of data to support routine exogenous melatonin supplementation. More clinical evidence to confirm the potential benefits of melatonin therapy is required before it can be routinely used in the postoperative or critically ill patient.

Keywords

Circadian rhythm Critical illness Delirium Melatonin Sepsis Sleep disorders 

References

  1. 1.
    Claustrat B, Brun J, David M, Sassolas G, Chazot G (1992) Melatonin and jet lag: confirmatory result using a simplified protocol. Biol Psychiatry 32:705–711PubMedCrossRefGoogle Scholar
  2. 2.
    Lissoni P, Barni S, Ardizzoia A, Paolorossi F, Crispino S, Tancini G, Tisi E, Archili C, De Toma D, Pipino G (1992) Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin. Oncology 49:336–339PubMedCrossRefGoogle Scholar
  3. 3.
    Dahlitz M, Alvarez B, Vignau J, English J, Arendt J, Parkes JD (1991) Delayed sleep phase syndrome response to melatonin. Lancet 337:1121–4PubMedCrossRefGoogle Scholar
  4. 4.
    Sack RL, Brandes RW, Kendall AR, Lewy AJ (2000) Entrainment of free-running circadian rhythms by melatonin in blind people. N Engl J Med 343:1070–7PubMedCrossRefGoogle Scholar
  5. 5.
    Garfinkel D, Laudon M, Nof D, Zisapel N (1995) Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet 346:541–544PubMedCrossRefGoogle Scholar
  6. 6.
    Reiter RJ, Tan DX, Sainz RM, Mayo JC, Lopez-Burillo S (2002) Melatonin: Reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol 54:1299–1321PubMedCrossRefGoogle Scholar
  7. 7.
    Naguib M, Samarkandi AH (1999) Premedication with melatonin: a double-blind, placebo-controlled comparison with midazolam. Br J Anaesth 82:875–80PubMedGoogle Scholar
  8. 8.
    Naguib M, Hammond DL, Schmid PG 3rd, Baker MT, Cutkomp J, Queral L, Smith T (2003) Pharmacological effects of intravenous melatonin: comparative studies with thiopental and propofol. Br J Anaesth 90:504–507PubMedCrossRefGoogle Scholar
  9. 9.
    Ryan DW (2002) Tried any melatonin lately? Care of the Critically Ill 18:132Google Scholar
  10. 10.
    Lane EA, Moss HB (1985) Pharmacokinetics of melatonin in man: first pass hepatic metabolism. J Clin Endocrinol METAB 61:1214–1216PubMedCrossRefGoogle Scholar
  11. 11.
    Sharma M, Palacios Bois J, Schwartz G, Iskandar H, Thakur M, Quirion R, Nair NP (1989) Circadian rhythms of melatonin and cortisol in aging. Biol Psychiatry 25:305–319PubMedCrossRefGoogle Scholar
  12. 12.
    Bubenik GA (2002) Gastrointestinal melatonin: localization, function, and clinical relevance. Dig Dis Sci 47:2336–2348PubMedCrossRefGoogle Scholar
  13. 13.
    Sack RL, Hughes RJ, Edgar DM, Lewy AJ (1997) Sleep-promoting effects of melatonin: at what dose, in whom, under what conditions, and by what mechanisms? Sleep 20:908–915PubMedGoogle Scholar
  14. 14.
    Pang SF, Dubocovich ML, Brown GM (1993) Melatonin receptors in peripheral tissues: a new area of melatonin research. Biol Signals 2:177–180PubMedCrossRefGoogle Scholar
  15. 15.
    Di WL, Djahanbakhch O, Kadva A, Street C, Silman R (1999) The pineal and extra-pineal origins of 5-sulphatoxy N-acetyl-serotonin in humans. J Pineal Res 26:221–226CrossRefGoogle Scholar
  16. 16.
    Di WL, Kadva A, Johnston A, Silman R (1997) Variable bioavailability of oral melatonin. N Engl J Med 336:1028–1029CrossRefGoogle Scholar
  17. 17.
    DeMuro RL, Nafziger AN, Blask DE, Menhinick AM, Bertino JS Jr (2000) The absolute bioavailability of oral melatonin. J Clin Pharmacol 40:781–784PubMedCrossRefGoogle Scholar
  18. 18.
    Hartter S, Ursing C, Morita S, Tybring G, von Bahr C, Christensen M, Rojdmark S, Bertilsson L (2001) Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot study. Clin Pharmacol Ther 70:10–16PubMedCrossRefGoogle Scholar
  19. 19.
    Bojkowski CJ, Arendt J, Shih MC, Markey SP (1987) Melatonin secretion in humans assessed by measuring its metabolite 6-sulphatoxymelatonin. Clin Chem 33:1343–1348PubMedGoogle Scholar
  20. 20.
    Mallo C, Zadan R, Galy G, Vermeulen E, Brun J, Chazot G, Claustrat B (1990) Pharmacokinetics of melatonin in man after intravenous infusion and bolus injection. Eur J Clin Pharmacol 38:297–301PubMedCrossRefGoogle Scholar
  21. 21.
    Iguchi H, Kato KI, Ibayashi H (1982) Melatonin serum levels and metabolic clearance rate in patients with liver cirrhosis. J Clin Endocrinol METAB 54:1025–1027PubMedCrossRefGoogle Scholar
  22. 22.
    Vakkuri O, Leppaluoto J, Kauppila A (1985) Oral administration and distribution of melatonin in human serum, saliva and urine. Life Sci 37:489–495PubMedCrossRefGoogle Scholar
  23. 23.
    Aldhous M, Franey C, Wright J, Arendt J (1985) Plasma concentrations of melatonin in man following oral absorption of different preparations. Br J Clin Pharmacol 19:517–521PubMedGoogle Scholar
  24. 24.
    Reiter RJ, Tan DX (2003) What constitutes a physiological concentration of melatonin? J Pineal Res 34:79–80PubMedCrossRefGoogle Scholar
  25. 25.
    Selmaoui B, Touitou Y (2003) Reproducibility of the circadian rhythms of serum cortisol and melatonin in healthy subjects: a study of three different 24-h cycles over six weeks. Life Sci 73:3339–3349PubMedCrossRefGoogle Scholar
  26. 26.
    Reber A, Huber PR, Ummenhofer W, Gurtler CM, Zurschmiede C, Drewe J, Schneider M (1998) General anaesthesia for surgery can influence circulating melatonin during daylight hours. Acta Anaesthesiol Scand 42:1050–1056PubMedCrossRefGoogle Scholar
  27. 27.
    Uchida K, Aoki T, Takahashi K, Iigo M, Hattori A, Suzuki T (1995) Perioperative plasma melatonin levels in patients with cardiac and esophageal surgery. St Marianna Med J 23:353–360Google Scholar
  28. 28.
    Guo X, Kuzumi E, Charman SC, Vuylsteke A (2002) Perioperative melatonin secretion in patients undergoing coronary artery bypass grafting. Anesth Analg 94:1085–1091PubMedCrossRefGoogle Scholar
  29. 29.
    Uchida K, Aoki T, Ishizuka B (1999) Postoperative delirium and plasma melatonin. Med Hypotheses 53:103–106PubMedCrossRefGoogle Scholar
  30. 30.
    Govitrapong P, Pariyanonth M, Ebadi M (1992) The presence and actions of opioid receptors in bovine pineal gland. J Pineal Res 13:124–132PubMedCrossRefGoogle Scholar
  31. 31.
    Brismar K, Hylander B, Eliasson K, Rossner S, Wetterberg L (1988) Melatonin secretion related to side effects of beta-blockers from the central nervous system. Acta Med Scand 223:525–530PubMedCrossRefGoogle Scholar
  32. 32.
    Stoschitzky K, Sakotnik A, Lercher P, Zweiker R, Maier R, Liebmann P, Lindner W (1999) Influence of beta-blockers on melatonin release. Eur J Clin Pharmacol 55:111–115PubMedCrossRefGoogle Scholar
  33. 33.
    McIntyre IM, Burrows GD, Norman TR (1988) Suppression of plasma melatonin by a single dose of the benzodiazepine alprazolam in humans. Biol Psychiatry. 24:108–112PubMedCrossRefGoogle Scholar
  34. 34.
    Monteleone P, Forziati D, Orazzo C, Maj M (1989) Preliminary observations on the suppression of nocturnal plasma melatonin levels by short-term administration of diazepam in humans. J Pineal Res 6:253–258PubMedCrossRefGoogle Scholar
  35. 35.
    Yuwiler A (1989) Effects of steroids on serotonin-N-acetyltransferase activity of pineals in organ culture. J Neurochem 52:46–53PubMedCrossRefGoogle Scholar
  36. 36.
    Iuvone PM, Besharse JC (1986) Involvement of calcium in the regulation of serotonin N- acetyltransferase in retina. J Neurochem 46:82–88PubMedCrossRefGoogle Scholar
  37. 37.
    Meyer AC, Nieuwenhuis JJ, Kociszewska VJ, Joubert WS, Meyer BJ (1986) Dihydropyridine calcium antagonists depress the amplitude of the plasma melatonin cycle in baboons. Life Sci 39:1563–1569PubMedCrossRefGoogle Scholar
  38. 38.
    Murphy PJ, Myers BL, Badia P (1996) Nonsteroidal anti-inflammatory drugs alter body temperature and suppress melatonin in humans. Physiol Behav 59:133–139PubMedCrossRefGoogle Scholar
  39. 39.
    Munoz-Hoyos A, Fernandez-Garcia JM, Molina-Carballo A, Macias M, Escames G, Ruiz-Cosano C, Acuna-Castroviejo D (2000) Effect of clonidine on plasma ACTH, cortisol and melatonin in children. J Pineal Res 29:48–53PubMedCrossRefGoogle Scholar
  40. 40.
    Monteleone P, Tortorella A, Borriello R, Natale M, Cassandro P, Maj M (1997) Suppression of nocturnal plasma melatonin levels by evening administration of sodium valproate in healthy humans. Biol Psychiatry 41:336–341PubMedCrossRefGoogle Scholar
  41. 41.
    Karkela J, Vakkuri O, Kaukinen S, Huang WQ, Pasanen M (2002) The influence of anaesthesia and surgery on the circadian rhythm of melatonin. Acta Anaesthesiol Scand 46:30–36PubMedCrossRefGoogle Scholar
  42. 42.
    Messner M, Huether G, Lorf T, Ramadori G, Schworer H (2001) Presence of melatonin in the human hepatobiliary-gastrointestinal tract. Life Sci 69:543–551PubMedCrossRefGoogle Scholar
  43. 43.
    Cronin AJ, Keifer JC, Davies MF, King TS, Bixler EO (2000) Melatonin secretion after surgery. Lancet 356:1244–1245PubMedCrossRefGoogle Scholar
  44. 44.
    Nishimura S, Fujino Y, Shimaoka M, Hagihira S, Taenaka N, Yoshiya I (1998) Circadian secretion patterns of melatonin after major surgery. J Pineal Res 25:73–77PubMedCrossRefGoogle Scholar
  45. 45.
    Miyazaki T, Kuwano H, Kato H, Ando H, Kimura H, Inose T, Ohno T, Suzuki M, Nakajima M, Manda R, Fukuchi M, Tsukada K (2003) Correlation between serum melatonin circadian rhythm and intensive care unit psychosis after thoracic esophagectomy. Surgery 133:662–668PubMedCrossRefGoogle Scholar
  46. 46.
    Derenzo J, Macknight B, DiVittore NA, Bonafide CP, Cronin AJ (2005) Postoperative elevated cortisol excretion is not associated with suppression of 6-sulfatoxymelatonin excretion. Acta Anaesthesiol Scand 49:52–57PubMedCrossRefGoogle Scholar
  47. 47.
    Kellner M, Yassouridis A, Manz B, Steiger A, Holsboer F, Wiedemann K (1997) Corticotropin-releasing hormone inhibits melatonin secretion in healthy volunteers—a potential link to low-melatonin syndrome in depression? Neuroendocrinology 65:284–290PubMedCrossRefGoogle Scholar
  48. 48.
    Rosenberg-Adamsen S, Kehlet H, Dodds C, Rosenberg J (1996) Postoperative sleep disturbances: mechanisms and clinical implications. Br J Anaesth 76:552–559PubMedGoogle Scholar
  49. 49.
    Mundigler G, Delle-Karth G, Koreny M, Zehetgruber M, Steindl-Munda P, Marktl W, Ferti L, Siostrzonek P (2002) Impaired circadian rhythm of melatonin secretion in sedated critically ill patients with severe sepsis. Crit Care Med 30:536–540PubMedCrossRefGoogle Scholar
  50. 50.
    Parfitt AG, Klein DC (1976) Sympathetic nerve endings in the pineal gland protect against acute stress-induced increase in N-acetyltransferase (EC 2.3.1.5.) activity. Endocrinology 99:840–851PubMedCrossRefGoogle Scholar
  51. 51.
    Berlin I, Touitou Y, Guillemant S, Danjou P, Puech AJ (1995) Beta-adrenoceptor agonists do not stimulate daytime melatonin secretion in healthy subjects. A double blind placebo controlled study. Life Sci 56:325–331CrossRefGoogle Scholar
  52. 52.
    Frisk U, Olsson J, Nylen P, Hahn RG (2004) Low melatonin excretion during mechanical ventilation in the intensive care unit. Clin Sci 107:47–53PubMedCrossRefGoogle Scholar
  53. 53.
    Sam S, Corbridge TC, Mokhlesi B, Comellas AP, Molitch ME (2004) Cortisol levels and mortality in severe sepsis. Clin Endocrinol (Oxf) 60:29–35CrossRefGoogle Scholar
  54. 54.
    Olofsson K, Alling C, Lundberg D, Malmros C (2004) Abolished circadian rhythm of melatonin secretion in sedated and artificially ventilated intensive care patients. Acta Anaesthesiol Scand 48:679–684PubMedCrossRefGoogle Scholar
  55. 55.
    Gabor JY, Cooper AB, Hanly PJ (2001) Sleep disruption in the intensive care unit. Curr Opin Crit Care 7:21–27PubMedCrossRefGoogle Scholar
  56. 56.
    Cooper AB, Thornley KS, Young GB, Slutsky AS, Stewart TE, Hanly PJ (2000) Sleep in critically ill patients requiring mechanical ventilation. Chest 117:809–818PubMedCrossRefGoogle Scholar
  57. 57.
    Shilo L, Dagan Y, Smorjik Y, Weinberg U, Dolev S, Komptel B, Balaum H, Shenkman L (1999) Patients in the intensive care unit suffer from severe lack of sleep associated with loss of normal melatonin secretion pattern. Am J Med Sci 317:278–281PubMedCrossRefGoogle Scholar
  58. 58.
    Shilo L, Dagan Y, Smorjik Y, Weinberg U, Dolev S, Komptel B, Shenkman L (2000) Effect of melatonin on sleep quality of COPD intensive care patients: a pilot study. Chronobiol Int 17:71–76PubMedCrossRefGoogle Scholar
  59. 59.
    MacFarlane JG, Cleghorn JM, Brown GM, Streiner DL (1991) The effects of exogenous melatonin on the total sleep time and daytime alertness of chronic insomniacs: A preliminary study. Biol Psychiatry 30:371–376PubMedCrossRefGoogle Scholar
  60. 60.
    Helfrich E, Neef C, Hylkema BS, Wilts G, Merkus FWHM (2004) Obtaining a normal sleep-wake pattern: Intranasal administration of melatonin in intensive care patients. Pharm Weekbl 139:82–85Google Scholar
  61. 61.
    Bourne RS, Mills GH (2004) Sleep disruption in critically ill patients—pharmacological considerations. Anaesthesia 59:374–384PubMedCrossRefGoogle Scholar
  62. 62.
    Zhdanova IV, Wurtman RJ, Morabito C, Piotrovska VR, Lynch HJ (1996) Effects of low oral doses of melatonin, given 2–4 h before habitual bedtime, on sleep in normal young humans. Sleep 19:423–431PubMedGoogle Scholar
  63. 63.
    Paul MA, Gray G, Kenny G, Pigeau RA (2003) Impact of melatonin, zaleplon, zopiclone, and temazepam on psychomotor performance. Aviat Space Environ Med 74:1263–1270PubMedGoogle Scholar
  64. 64.
    Cajochen C, Kräuchi K, Wirz Justice A (2003) Role of melatonin in the regulation of human circadian rhythms and sleep. J Neuroendocrinol 15:432–437PubMedCrossRefGoogle Scholar
  65. 65.
    Ely EW, Shintani A, Truman B, Speroff T, Gordon SM, Harrell FE Jr, Inouye SK, Bernard GR, Dittus RS (2004) Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA 291:1753–1762PubMedCrossRefGoogle Scholar
  66. 66.
    Jacobi J, Fraser GL, Coursin DB, Riker RR, Fontaine D, Wittbrodt ET, Chalfin DB, Masica MF, Bjerke HS, Coplin WM, Crippen DW, Fuchs BD, Kelleher RM, Marik PE, Nasraway SA Jr, Murray-Michael J, Peruzzi WT, Lumb PD (2002) Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med 30:119–141PubMedCrossRefGoogle Scholar
  67. 67.
    Miles A, Philbrick DRS (1988) Melatonin and psychiatry. Biol Psychiatry 23:405–425PubMedCrossRefGoogle Scholar
  68. 68.
    Shigeta H, Yasui A, Nimura Y, Machida N, Kageyama M, Miura M, Menjo M, Ikeda K (2001) Postoperative delirium and melatonin levels in elderly patients. Am J Surg 182:449–454PubMedCrossRefGoogle Scholar
  69. 69.
    Balan S, Leibovitz A, Zila SO, Ruth M, Chana W, Yassica B, Rahel B, Richard G, Neumann E, Blagman B, Habot B (2003) The relation between the clinical subtypes of delirium and the urinary level of 6-SMT. J Neuropsychiatry Clin Neurosci 15:363–366PubMedGoogle Scholar
  70. 70.
    Lewis MC, Barnett SR (2004) Postoperative delirium: The tryptophan dyregulation model. Med Hypotheses 63:402–406PubMedCrossRefGoogle Scholar
  71. 71.
    Hanania M, Kitain E (2002) Melatonin for treatment and prevention of postoperative delirium. Anesth Analg 94:338–339PubMedCrossRefGoogle Scholar
  72. 72.
    McGuire BE, Basten CJ, Ryan CJ, Gallagher J (2000) Intensive care unit syndrome: a dangerous misnomer. Arch Intern Med 160:906–909PubMedCrossRefGoogle Scholar
  73. 73.
    Lundstrom M, Edlund A, Karlsson S, Brannstrom B, Bucht G, Gustafson Y (2005) A multifactorial intervention program reduces the duration of delirium, length of hospitalization, and mortality in delirious patients. J Am Geriatr Soc 53:622–628PubMedCrossRefGoogle Scholar
  74. 74.
    Macdonald J, Galley HF, Webster NR (2003) Oxidative stress and gene expression in sepsis. Br J Anaesth 90:221–232PubMedCrossRefGoogle Scholar
  75. 75.
    Cowley HC, Bacon PJ, Goode HF, Webster NR, Jones JG, Menon DK (1996) Plasma antioxidant potential in severe sepsis: a comparison of survivors and nonsurvivors. Crit Care Med 24:1179–1183PubMedCrossRefGoogle Scholar
  76. 76.
    Pascual C, Karzai W, Meier-Hellmann A, Oberhoffer M, Horn A, Bredle D, Reinhart K (1998) Total plasma antioxidant capacity is not always decreased in sepsis. Crit Care Med 26:705–709PubMedCrossRefGoogle Scholar
  77. 77.
    Sewerynek E, Melchiorri D, Reiter RJ, Ortiz GG, Lewinski A (1995) Lipopolysaccharide-induced hepatotoxicity is inhibited by the antioxidant melatonin. Eur J Pharmacol 293:327–334PubMedCrossRefGoogle Scholar
  78. 78.
    Yerer MB, Aydogan S, Yapislar H, Yalcin O, Kuru O, Baskurt OK (2003) Melatonin increases glutathione peroxidase activity and deformability of erythrocytes in septic rats. J Pineal Res 35:138–139PubMedCrossRefGoogle Scholar
  79. 79.
    Paskaloglu K, Sener G, Kapucu C, Ayanoglu-Dulger G (2004) Melatonin treatment protects against sepsis-induced functional and biochemical changes in rat ileum and urinary bladder. Life Sci 74:1093–1104PubMedCrossRefGoogle Scholar
  80. 80.
    Acikel M, Buyukokuroglu ME, Aksoy H, Erdogan F, Erol MK (2003) Protective effects of melatonin against myocardial injury induced by isoproterenol in rats. J Pineal Res 35:75–79PubMedCrossRefGoogle Scholar
  81. 81.
    Gitto E, Karbownik M, Reiter RJ, Tan DX, Cuzzocrea S, Chiurazzi P, Cordaro S, Corona G, Trimarchi G, Barberi I (2001) Effects of melatonin treatment in septic newborns. Pediatr Res 50:756–760PubMedCrossRefGoogle Scholar
  82. 82.
    Hotchkiss RS, Karl IE (2003) The pathophysiology and treatment of sepsis. N Engl J Med 348:138–150PubMedCrossRefGoogle Scholar
  83. 83.
    Jahnke G, Marr M, Myers C, Wilson R, Travlos G, Price C (1999) Maternal and developmental toxicity evaluation of melatonin administered orally to pregnant Sprague-Dawley rats. Toxicol Sci 50:271–279PubMedCrossRefGoogle Scholar
  84. 84.
    Albuszies G, Bruckner UB (2003) Antioxidant therapy in sepsis. Intensive Care Med 29:1632–1636PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  1. 1.Intensive Care Unit, R FloorRoyal Hallamshire HospitalSheffieldUK
  2. 2.Medical Economics and Research Centre, Sheffield (MERCS), R FloorRoyal Hallamshire HospitalSheffieldUK

Personalised recommendations